Alprenolol, a new beta adrenergic receptor blocking agent, was evaluated as an antiarrhythmic drug in 49 patients with 78 episodes of premature contractions or tachyarrhythmias of supraventricular or ventricular origin. A clinically and statistically significant reduction in frequency of premature contractions was obtained. In addition, a clinically and statistically significant reduction in ventricular rate occurred in those patients with tachyarrhythmias. No severe adverse effects were noted during the study. The results indicate that alprenolol can be used safely and effectively in the treatment of cardiac arrhythmias occurring during acute myocardial infarction. Congestive heart failure was not considered a contraindication when it was judged clinically that the arrhythmia aggravated the heart failure.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine